Literature DB >> 25726050

Pathological and molecular evaluation of pancreatic neoplasms.

Arvind Rishi1, Michael Goggins2, Laura D Wood2, Ralph H Hruban3.   

Abstract

Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecular pathogenesis brings new opportunities for early detection, improved prognostication, and personalized gene-specific therapies. Here we review the pathological classification of pancreatic neoplasms from the molecular and genetic perspectives.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2014        PMID： 25726050      PMCID： PMC4450719          DOI： 10.1053/j.seminoncol.2014.12.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  111 in total

1.  Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Suresh T Chari; Dhiraj Yadav; Thomas C Smyrk; Eugene P DiMagno; Laurence J Miller; Massimo Raimondo; Jonathan E Clain; Ian A Norton; Randall K Pearson; Bret T Petersen; Maurits J Wiersema; Michael B Farnell; Michael G Sarr
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

2.  Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas.

Authors:  Yan Guo; Fei Yuan; Huan Deng; Hua-Feng Wang; Xiao-Long Jin; Jia-Cheng Xiao
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

3.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Pancreatic cysts: depiction on single-shot fast spin-echo MR images.

Authors:  Xiao-Ming Zhang; Donald G Mitchell; Masako Dohke; George A Holland; Laurence Parker
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

5.  Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Authors:  Maria C Villarroel; N V Rajeshkumar; Ignacio Garrido-Laguna; Ana De Jesus-Acosta; Siân Jones; Anirban Maitra; Ralph H Hruban; James R Eshleman; Alison Klein; Daniel Laheru; Ross Donehower; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-12-06       Impact factor: 6.261

6.  Pancreatoblastoma: a report from the European cooperative study group for paediatric rare tumours (EXPeRT).

Authors:  Ewa Bien; Jan Godzinski; Patrizia Dall'igna; Anne-Sophie Defachelles; Teresa Stachowicz-Stencel; Daniel Orbach; Gianni Bisogno; Giovanni Cecchetto; Steven Warmann; Verena Ellerkamp; Bernadette Brennan; Anna Balcerska; Malgorzata Rapala; Ines Brecht; Dominik Schneider; Andrea Ferrari
Journal:  Eur J Cancer       Date:  2011-06-21       Impact factor: 9.162

7.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

8.  Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.

Authors:  Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

9.  Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors.

Authors:  Christine A Iacobuzio-Donahue; Jason Song; Giovanni Parmiagiani; Charles J Yeo; Ralph H Hruban; Scott E Kern
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

10.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962
View more
  23 in total

1.  Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges.

Authors:  Sandrina Maertin; Jason M Elperin; Ethan Lotshaw; Matthias Sendler; Steven D Speakman; Kazuki Takakura; Benjamin M Reicher; Olga A Mareninova; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-07-13       Impact factor: 4.052

2.  Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

Authors:  Lei Miao; Jingjing Li; Qi Liu; Richard Feng; Manisit Das; C Michael Lin; Tyler J Goodwin; Oleksandra Dorosheva; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2017-08-28       Impact factor: 15.881

3.  Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?

Authors:  Leticia M Nogueira; Christina C Newton; Michael Pollak; Debra T Silverman; Demetrius Albanes; Satu Männistö; Stephanie J Weinstein; Eric J Jacobs; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-17       Impact factor: 4.254

Review 4.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

Review 5.  Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.

Authors:  Kelly E Craven; Jesse Gore; Murray Korc
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

6.  IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia.

Authors:  Yuliya Pylayeva-Gupta; Shipra Das; Jesse S Handler; Cristina H Hajdu; Maryaline Coffre; Sergei B Koralov; Dafna Bar-Sagi
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

Review 7.  Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon.

Authors:  Anna La Salvia; Irene Persano; Elena Parlagreco; Alessandro Audisio; Massimiliano Cani; Maria Pia Brizzi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 8.  Pancreatic cancer: Are "liquid biopsies" ready for prime-time?

Authors:  Alexandra R Lewis; Juan W Valle; Mairead G McNamara
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Authors:  Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Thomas Schmidt; Lilli Podola; Tobias Friedrich; Heinz Lubenau; Marco Springer; Sébastien Wieckowski; Klaus M Breiner; Gerd Mikus; Markus W Büchler; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Phillip Knebel; Mariana Bucur; Lars Grenacher; Walter E Haefeli; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

10.  Mixed acinar-endocrine carcinoma of pancreas: A case report and brief review of the literature.

Authors:  Zhenzhen Liu; Chengyong Dong; Chengye Wang; Qinlong Liu; Deguang Sun; Liming Wang
Journal:  Onco Targets Ther       Date:  2015-07-03       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.